Takeda Oncology Partner Page 2020

The Global Resource for Advancing Cancer Education (GRACE)

Where Education is Medicine.

GRACE is pleased to work with Takeda Oncology to present the following information.

Background - What is ALK?

Case Based Panel Discussion - 2019 ALK Positive with Brain Mets, Radiation before ALK Inhibitor?

Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

Lung Cancer Video Library - ALK Rearrangements: What Are They, and Who Has Them?

David Ross Camidge, MD, PhD, GRACE Faculty

Current and Emerging Approaches to Acquired Resistance for ALK/ROS1

GRACE Videos and Articles

The Blood/Brain Barrier for ALK Patients

GRACE Videos and Articles

Panel Q&A Session on ALK+ and ROS1 Acquired Resistance with Drs. Horn and Owonikoko

GRACE Videos and Articles

Targeted Therapies in Lung Cancer Patient Forum 2016 - Breakout session ALK+ part 1

Denise Brock

Targeted Therapies in Lung Cancer Patient Forum 2016 - Breakout session ALK+ part 2

Denise Brock

Mechanisms of ALK Resistance & Implications for Treatment

Robert C. Doebele, M.D., Ph.D., GRACE Faculty

Dr. Ben Solomon on ALK Inhibition: From Science to Effective Treatment for ALK-Positive NSCLC

Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

Testing and Biopsying

How do you approach acquired resistance to a targeted therapy in lung cancer? Follow the algorithm!

Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

Dr. David Spigel: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?

GRACE Videos and Articles

ALK Positive Lung Cancer Forum 2014: Repeat Biopsies

Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

Dr. Geoffrey Oxnard: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?

GRACE Videos and Articles

Lung Cancer Video Library - AGGARWAL - Utility of Liquid Biopsies

Charu Aggarwal, MD, MPH, GRACE Faculty

Lung Cancer Video Library 2017 - Liquid Biopsies for Broad Genomic Testing in Lung Cancer

Nathan Pennell, MD, Ph.D., GRACE Faculty

Treatment

Lung Cancer Video Library 2020 - LEVY - Immunotherapy Combinations for Advanced NSCLC

Benjamin Levy, MD, Faculty

Lung Cancer Video Library 2020 - LEVY - Immunotherapy in Patients with Driver Mutations

Benjamin Levy, MD, Faculty

Case Based Panel Discussion 2019 - Progression Post ALK Inhibitor - Role For Combination Therapies?

Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

Case Based Panel Discussion - 2019 ALK Positive, Progression after Success on ALK Inhibitor

Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

Case Based Panel Discussion –ALK Positive, High PD-L1:First Line Treatment for Competing Targets

Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

Case Based Panel Discussions - 2019 ALK Pos, Developing Resistance to ALK Inhibitors and Next Steps

Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

Lung Cancer Video Library - Das - The Role of Immunotherapy for Unresectable Stage 3 NSCLC Today

Millie Das, MD, Guest Faculty

Lung Cancer Video Library - Das - Treatments - Low or Negative PDL1 and Advanced Non-Squamous NSCLC

Millie Das, MD, Guest Faculty

Are There Clinically Significant Differences Among the Second Generation ALK Inhibitors?

GRACE Videos and Articles

Should Alecensa (Alectinib) be the new first line ALK inhibitor for ALK-positive NSCLC?

Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

Radiation to Address Cells with Resistance to Targeted Therapies

Jared Weiss, MD, Associate Professor Clinical Research Hematology/Oncology

Access & Assistance for ALK+, ROS1 & EGFR Patients

GRACE Videos and Articles

ALK Positive Lung Cancer Forum 2014: ALK Rearrangements in Lung Cancer

GRACE Videos and Articles

ALK Positive Lung Cancer Forum 2014: Next Generation ALK Inhibitors

GRACE Videos and Articles

ALK Positive Lung Cancer Forum 2014: Repeat Biopsies

Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

Life After 1st Line Targeted Therapy: What Next?

Jared Weiss, MD, Associate Professor Clinical Research Hematology/Oncology

Mechanisms of ALK Resistance & Implications for Treatment

Robert C. Doebele, M.D., Ph.D., GRACE Faculty

What is Acquired Resistance to Targeted Therapy, and Why Does it Occur?

GRACE Videos and Articles

ASCO 2017 - Lung Cancer - Sequencing Treatments for ALK+ Lung Cancer in a Crowded Field - Is there a place for Lorlatinib?

Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

What is Acquired Resistance and How Does it Occur?

Gregory J. Riely, MD, PhD, GRACE Faculty

ASCO 2017 - Lung Cancer - A Practice Change for ALK+ Lung Cancer Patients, Alecensa for First Line Treatment

Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

Are there Clinically Significant Differences Among Immune Checkpoint Inhibitors Treating Lung Cancer?

GRACE Videos and Articles

Are There Clinically Significant Differences Among the Second Generation ALK Inhibitors?

GRACE Videos and Articles

Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?

GRACE Videos and Articles

Local Therapy After Progression